AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

was the centerpiece of the ProfoundBio deal. AbbVie acquired an ADC against the same target when it paid $10.1 billion for ImmunoGen in 2022.

cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total. AbbVie expects adjusted annual profit in the range of $11.99 to $12. ...